Cargando…
Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study
BACKGROUND: Type 3 von Willebrand disease (VWD) is a severe bleeding disorder caused by the virtually complete absence of von Willebrand factor (VWF). Pathophysiological mechanisms of VWD like defective synthesis, secretion, and clearance of VWF have previously been evaluated using ratios of VWF pro...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305521/ https://www.ncbi.nlm.nih.gov/pubmed/35092343 http://dx.doi.org/10.1111/jth.15658 |
_version_ | 1784752345859489792 |
---|---|
author | Pagliari, Maria Teresa Rosendaal, Frits R. Ahmadinejad, Minoo Badiee, Zahra Baghaipour, Mohammad‐Reza Baronciani, Luciano Benítez Hidalgo, Olga Bodó, Imre Budde, Ulrich Castaman, Giancarlo Eshghi, Peyman Goudemand, Jenny Karimi, Mehran Keikhaei, Bijan Lassila, Riitta Leebeek, Frank W. G. Lopez Fernandez, Maria Fernanda Mannucci, Pier Mannuccio Marino, Renato Oldenburg, Johannes Peake, Ian Santoro, Cristina Schneppenheim, Reinhard Tiede, Andreas Toogeh, Gholamreza Tosetto, Alberto Trossaert, Marc Yadegari, Hamideh Zetterberg, Eva M. K. Peyvandi, Flora Federici, Augusto B. Eikenboom, Jeroen |
author_facet | Pagliari, Maria Teresa Rosendaal, Frits R. Ahmadinejad, Minoo Badiee, Zahra Baghaipour, Mohammad‐Reza Baronciani, Luciano Benítez Hidalgo, Olga Bodó, Imre Budde, Ulrich Castaman, Giancarlo Eshghi, Peyman Goudemand, Jenny Karimi, Mehran Keikhaei, Bijan Lassila, Riitta Leebeek, Frank W. G. Lopez Fernandez, Maria Fernanda Mannucci, Pier Mannuccio Marino, Renato Oldenburg, Johannes Peake, Ian Santoro, Cristina Schneppenheim, Reinhard Tiede, Andreas Toogeh, Gholamreza Tosetto, Alberto Trossaert, Marc Yadegari, Hamideh Zetterberg, Eva M. K. Peyvandi, Flora Federici, Augusto B. Eikenboom, Jeroen |
author_sort | Pagliari, Maria Teresa |
collection | PubMed |
description | BACKGROUND: Type 3 von Willebrand disease (VWD) is a severe bleeding disorder caused by the virtually complete absence of von Willebrand factor (VWF). Pathophysiological mechanisms of VWD like defective synthesis, secretion, and clearance of VWF have previously been evaluated using ratios of VWF propeptide (VWFpp) over VWF antigen (VWF:Ag) and factor (F)VIII coagulant activity (FVIII:C) over VWF:Ag. OBJECTIVE: To investigate whether the VWFpp/VWF:Ag and FVIII:C/VWF:Ag ratios may also be applied to understand the pathophysiological mechanism underlying type 3 VWD and whether VWFpp is associated with bleeding severity. METHODS: European and Iranian type 3 patients were enrolled in the 3WINTERS‐IPS study. Plasma samples and buffy coats were collected and a bleeding assessment tool was administered at enrolment. VWF:Ag, VWFpp, FVIII:C, and genetic analyses were performed centrally, to confirm patients’ diagnoses. VWFpp/VWF:Ag and FVIII:C/VWF:Ag ratios were compared among different variant classes using the Mann‐Whitney test. Median differences with 95% confidence intervals (CI) were estimated using the Hodges‐Lehmann method. VWFpp association with bleeding symptoms was assessed using Spearman’s rank correlation. RESULTS: Homozygosity/compound heterozygosity for missense variants showed higher VWFpp level and VWFpp/VWF:Ag ratio than homozygosity/compound heterozygosity for null variants ([VWFpp median difference, 1.4 IU/dl; 95% CI, 0.2–2.7; P = .016]; [VWFpp/VWF:Ag median difference, 1.4; 95% CI, 0–4.2; P = .054]). FVIII:C/VWF:Ag ratio was similarly increased in both. VWFpp level did not correlate with the bleeding symptoms (r = .024; P = .778). CONCLUSIONS: An increased VWFpp/VWF:Ag ratio is indicative of missense variants, whereas FVIII:C/VWF:Ag ratio does not discriminate missense from null alleles. The VWFpp level was not associated with the severity of bleeding phenotype. |
format | Online Article Text |
id | pubmed-9305521 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93055212022-07-28 Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study Pagliari, Maria Teresa Rosendaal, Frits R. Ahmadinejad, Minoo Badiee, Zahra Baghaipour, Mohammad‐Reza Baronciani, Luciano Benítez Hidalgo, Olga Bodó, Imre Budde, Ulrich Castaman, Giancarlo Eshghi, Peyman Goudemand, Jenny Karimi, Mehran Keikhaei, Bijan Lassila, Riitta Leebeek, Frank W. G. Lopez Fernandez, Maria Fernanda Mannucci, Pier Mannuccio Marino, Renato Oldenburg, Johannes Peake, Ian Santoro, Cristina Schneppenheim, Reinhard Tiede, Andreas Toogeh, Gholamreza Tosetto, Alberto Trossaert, Marc Yadegari, Hamideh Zetterberg, Eva M. K. Peyvandi, Flora Federici, Augusto B. Eikenboom, Jeroen J Thromb Haemost HAEMOSTASIS BACKGROUND: Type 3 von Willebrand disease (VWD) is a severe bleeding disorder caused by the virtually complete absence of von Willebrand factor (VWF). Pathophysiological mechanisms of VWD like defective synthesis, secretion, and clearance of VWF have previously been evaluated using ratios of VWF propeptide (VWFpp) over VWF antigen (VWF:Ag) and factor (F)VIII coagulant activity (FVIII:C) over VWF:Ag. OBJECTIVE: To investigate whether the VWFpp/VWF:Ag and FVIII:C/VWF:Ag ratios may also be applied to understand the pathophysiological mechanism underlying type 3 VWD and whether VWFpp is associated with bleeding severity. METHODS: European and Iranian type 3 patients were enrolled in the 3WINTERS‐IPS study. Plasma samples and buffy coats were collected and a bleeding assessment tool was administered at enrolment. VWF:Ag, VWFpp, FVIII:C, and genetic analyses were performed centrally, to confirm patients’ diagnoses. VWFpp/VWF:Ag and FVIII:C/VWF:Ag ratios were compared among different variant classes using the Mann‐Whitney test. Median differences with 95% confidence intervals (CI) were estimated using the Hodges‐Lehmann method. VWFpp association with bleeding symptoms was assessed using Spearman’s rank correlation. RESULTS: Homozygosity/compound heterozygosity for missense variants showed higher VWFpp level and VWFpp/VWF:Ag ratio than homozygosity/compound heterozygosity for null variants ([VWFpp median difference, 1.4 IU/dl; 95% CI, 0.2–2.7; P = .016]; [VWFpp/VWF:Ag median difference, 1.4; 95% CI, 0–4.2; P = .054]). FVIII:C/VWF:Ag ratio was similarly increased in both. VWFpp level did not correlate with the bleeding symptoms (r = .024; P = .778). CONCLUSIONS: An increased VWFpp/VWF:Ag ratio is indicative of missense variants, whereas FVIII:C/VWF:Ag ratio does not discriminate missense from null alleles. The VWFpp level was not associated with the severity of bleeding phenotype. John Wiley and Sons Inc. 2022-02-22 2022-05 /pmc/articles/PMC9305521/ /pubmed/35092343 http://dx.doi.org/10.1111/jth.15658 Text en © 2022 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | HAEMOSTASIS Pagliari, Maria Teresa Rosendaal, Frits R. Ahmadinejad, Minoo Badiee, Zahra Baghaipour, Mohammad‐Reza Baronciani, Luciano Benítez Hidalgo, Olga Bodó, Imre Budde, Ulrich Castaman, Giancarlo Eshghi, Peyman Goudemand, Jenny Karimi, Mehran Keikhaei, Bijan Lassila, Riitta Leebeek, Frank W. G. Lopez Fernandez, Maria Fernanda Mannucci, Pier Mannuccio Marino, Renato Oldenburg, Johannes Peake, Ian Santoro, Cristina Schneppenheim, Reinhard Tiede, Andreas Toogeh, Gholamreza Tosetto, Alberto Trossaert, Marc Yadegari, Hamideh Zetterberg, Eva M. K. Peyvandi, Flora Federici, Augusto B. Eikenboom, Jeroen Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study |
title | Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study |
title_full | Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study |
title_fullStr | Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study |
title_full_unstemmed | Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study |
title_short | Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study |
title_sort | von willebrand factor propeptide and pathophysiological mechanisms in european and iranian patients with type 3 von willebrand disease enrolled in the 3winters‐ips study |
topic | HAEMOSTASIS |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305521/ https://www.ncbi.nlm.nih.gov/pubmed/35092343 http://dx.doi.org/10.1111/jth.15658 |
work_keys_str_mv | AT pagliarimariateresa vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT rosendaalfritsr vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT ahmadinejadminoo vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT badieezahra vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT baghaipourmohammadreza vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT baroncianiluciano vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT benitezhidalgoolga vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT bodoimre vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT buddeulrich vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT castamangiancarlo vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT eshghipeyman vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT goudemandjenny vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT karimimehran vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT keikhaeibijan vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT lassilariitta vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT leebeekfrankwg vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT lopezfernandezmariafernanda vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT mannuccipiermannuccio vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT marinorenato vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT oldenburgjohannes vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT peakeian vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT santorocristina vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT schneppenheimreinhard vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT tiedeandreas vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT toogehgholamreza vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT tosettoalberto vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT trossaertmarc vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT yadegarihamideh vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT zetterbergevamk vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT peyvandiflora vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT federiciaugustob vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy AT eikenboomjeroen vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy |